دورية أكاديمية

Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial

التفاصيل البيبلوغرافية
العنوان: Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial
المؤلفون: Hobbs, F. D. Richard, Montgomery, Hugh, Padilla, Francisco, Simón-Campos, Jesus Abraham, Kim, Kenneth, Arbetter, Douglas, Padilla, Kelly W., Reddy, Venkatesh Pilla, Seegobin, Seth, Streicher, Katie, Templeton, Alison, Viani, Rolando M., Johnsson, Eva, Koh, Gavin C. K. W., Esser, Mark T.
المساهمون: AstaZeneca
المصدر: Infectious Diseases and Therapy ; volume 12, issue 9, page 2269-2287 ; ISSN 2193-8229 2193-6382
بيانات النشر: Springer Science and Business Media LLC
سنة النشر: 2023
مصطلحات موضوعية: Infectious Diseases, Microbiology (medical)
نوع الوثيقة: article in journal/newspaper
اللغة: English
DOI: 10.1007/s40121-023-00861-7
DOI: 10.1007/s40121-023-00861-7.pdf
DOI: 10.1007/s40121-023-00861-7/fulltext.html
الإتاحة: https://doi.org/10.1007/s40121-023-00861-7Test
حقوق: https://creativecommons.org/licenses/by-nc/4.0Test ; https://creativecommons.org/licenses/by-nc/4.0Test
رقم الانضمام: edsbas.27160446
قاعدة البيانات: BASE